OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
PARP Inhibitors Resistance: Mechanisms and Perspectives
Elena Giudice, Marica Gentile, Vanda Salutari, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1420-1420
Open Access | Times Cited: 49
Elena Giudice, Marica Gentile, Vanda Salutari, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1420-1420
Open Access | Times Cited: 49
Showing 1-25 of 49 citing articles:
Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Sayra Dilmaç, Bülent Özpolat
Cancers (2023) Vol. 15, Iss. 14, pp. 3642-3642
Open Access | Times Cited: 23
Sayra Dilmaç, Bülent Özpolat
Cancers (2023) Vol. 15, Iss. 14, pp. 3642-3642
Open Access | Times Cited: 23
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
DNA Adducts in Cancer Chemotherapy
Yupeng Li
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5113-5143
Closed Access | Times Cited: 11
Yupeng Li
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5113-5143
Closed Access | Times Cited: 11
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102623-102623
Open Access | Times Cited: 17
Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102623-102623
Open Access | Times Cited: 17
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Jie Zhang, Yuqi Gao, Zipeng Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16099-16127
Closed Access | Times Cited: 22
Jie Zhang, Yuqi Gao, Zipeng Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16099-16127
Closed Access | Times Cited: 22
PARP inhibitors in ovarian cancer
Ian S. Goldlust, Elena Guidice, Jung‐Min Lee
Seminars in Oncology (2024) Vol. 51, Iss. 1-2, pp. 45-57
Closed Access | Times Cited: 4
Ian S. Goldlust, Elena Guidice, Jung‐Min Lee
Seminars in Oncology (2024) Vol. 51, Iss. 1-2, pp. 45-57
Closed Access | Times Cited: 4
Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Overview of Roles of Novel Components in the Regulation of DNA Damage Repair in BRCA1-Deficient Cancers: An Update
N. V. Nguyen, Dominic Arris, Manh Tien Tran
DNA (2025) Vol. 5, Iss. 2, pp. 17-17
Open Access
N. V. Nguyen, Dominic Arris, Manh Tien Tran
DNA (2025) Vol. 5, Iss. 2, pp. 17-17
Open Access
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
Ruiting Fu, Ranliang Hu, Wenting Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Ruiting Fu, Ranliang Hu, Wenting Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Role of PARP-1 structural and functional features in PARP-1 inhibitors development
Alexander Vladimirovich Merkuryev, Egorov Vv
Bioorganic Chemistry (2025) Vol. 156, pp. 108188-108188
Closed Access
Alexander Vladimirovich Merkuryev, Egorov Vv
Bioorganic Chemistry (2025) Vol. 156, pp. 108188-108188
Closed Access
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches
Adam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Cancer Drug Resistance (2025)
Open Access
Adam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Cancer Drug Resistance (2025)
Open Access
Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer
Federica Carbone, Pietro Ancona, Stefano Volinia, et al.
Biology (2025) Vol. 14, Iss. 3, pp. 253-253
Open Access
Federica Carbone, Pietro Ancona, Stefano Volinia, et al.
Biology (2025) Vol. 14, Iss. 3, pp. 253-253
Open Access
Targeting DNA repair mechanisms: Spirobenzoxazinone and salicylamide derivatives as novel candidates for PARP-1 inhibition in cancer therapy
Abdelrazak M. Kadry, Mai Adel, Samar A. Abubshait, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118173-118173
Closed Access
Abdelrazak M. Kadry, Mai Adel, Samar A. Abubshait, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118173-118173
Closed Access
Clinical differences among the PARP inhibitors in the first-line treatment of advanced-stage ovarian carcinoma
John P. Micha, Mark A. Rettenmaier, Randy Bohart, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
John P. Micha, Mark A. Rettenmaier, Randy Bohart, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Targeting base excision repair in precision oncology
Nicola P. Montaldo, Hilde Nilsen, Diana L. Bordin
DNA repair (2025), pp. 103844-103844
Open Access
Nicola P. Montaldo, Hilde Nilsen, Diana L. Bordin
DNA repair (2025), pp. 103844-103844
Open Access
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
Gilda Magliacane, Emanuela Brunetto, Silvia Calzavara, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 43-43
Open Access | Times Cited: 16
Gilda Magliacane, Emanuela Brunetto, Silvia Calzavara, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 43-43
Open Access | Times Cited: 16
PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
Qi Cao, Lanyang Li, Yuqing Zhao, et al.
Cell Transplantation (2023) Vol. 32
Open Access | Times Cited: 9
Qi Cao, Lanyang Li, Yuqing Zhao, et al.
Cell Transplantation (2023) Vol. 32
Open Access | Times Cited: 9
The potential of PARP as a therapeutic target across pediatric solid malignancies
Kaylee M. Keller, Joost Koetsier, Linda Schild, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Kaylee M. Keller, Joost Koetsier, Linda Schild, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
The proofreading exonuclease of leading-strand DNA polymerase epsilon prevents replication fork collapse at broken template strands
Tasnim Ahmad, Ryotaro Kawasumi, Tomoya Taniguchi, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 22, pp. 12288-12302
Open Access | Times Cited: 7
Tasnim Ahmad, Ryotaro Kawasumi, Tomoya Taniguchi, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 22, pp. 12288-12302
Open Access | Times Cited: 7
Targeting selective inhibitors of PARPs in drug discovery and development
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition
Xixi Lin, Aashish Soni, Razan Hessenow, et al.
Radiotherapy and Oncology (2024) Vol. 200, pp. 110475-110475
Open Access | Times Cited: 2
Xixi Lin, Aashish Soni, Razan Hessenow, et al.
Radiotherapy and Oncology (2024) Vol. 200, pp. 110475-110475
Open Access | Times Cited: 2
Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib
Vlad-Adrian Afrăsânie, Alexandra Rusu, Adelina Silvana Gheorghe, et al.
Diagnostics (2024) Vol. 14, Iss. 17, pp. 1898-1898
Open Access | Times Cited: 2
Vlad-Adrian Afrăsânie, Alexandra Rusu, Adelina Silvana Gheorghe, et al.
Diagnostics (2024) Vol. 14, Iss. 17, pp. 1898-1898
Open Access | Times Cited: 2
An update on small molecule compounds targeting synthetic lethality for cancer therapy
Jiaxiang Luo, Yang Li, Yiwen Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116804-116804
Closed Access | Times Cited: 2
Jiaxiang Luo, Yang Li, Yiwen Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116804-116804
Closed Access | Times Cited: 2
ATR Inhibitors in Platinum-Resistant Ovarian Cancer
Siyu Li, Tao Wang, Xichang Fei, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5902-5902
Open Access | Times Cited: 10
Siyu Li, Tao Wang, Xichang Fei, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5902-5902
Open Access | Times Cited: 10
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Shicheng Yang, Allen Green, Needa Brown, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Shicheng Yang, Allen Green, Needa Brown, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
